Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vormatrigine in Adults With Focal Seizures
NCT07505004Phase 3Active, not recruiting
- Sponsor
- Praxis Precision Medicines
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vormatrigine in focal epilepsy (4 arms), sponsored by Praxis Precision Medicines. Primary endpoint: Focal Seizure Frequency at 12 weeks. Started Jan 2026; status: active, not recruiting.
02
Drugs
vormatrigine
03
Conditions
focal epilepsy
Beyond the preview
Go deeper on NCT07505004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07505004.